Abstract
It is reported that 7,8-dihydroxyflavone (DHF), a TrkB agonist, has beneficial effects on neuronal excitotoxicity, stroke, and Parkinson disease in animal models by enhancing axon regeneration, muscle reinnervation and neuromuscular transmission. The effect of DHF on AD neuropathology remains not well defined. In this study we examined whether DHF affects APP processing and cognitive functions in vitro and in vivo. We found that DHF had no significant effect on amyloid β precursor protein (APP), BACE1 and amyloid β protein (Aβ). DHF had little effect on APP processing in cell cultures. DHF treatment did not reduce the deposition of Aβ to form neuritic plaques in the brain of AD model mice APP23/PS45. Furthermore, DHF did not alleviate learning and memory impairments in the AD model mice. Our study suggest that further extensive and careful studies are warranted for considering DHF as a new therapeutic agent for reducing amyloid pathology and alleviating cognitive deficits for AD treatment.
Keywords: Aβ, Alzheimer’s disease, 7, 8-dihydroxyflavone, memory deficits.
Current Alzheimer Research
Title:No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Volume: 12 Issue: 1
Author(s): Weitao Zhou, Xiaoyong Li, Daochao Huang, Weihui Zhou, Tingyu Li and Weihong Song
Affiliation:
Keywords: Aβ, Alzheimer’s disease, 7, 8-dihydroxyflavone, memory deficits.
Abstract: It is reported that 7,8-dihydroxyflavone (DHF), a TrkB agonist, has beneficial effects on neuronal excitotoxicity, stroke, and Parkinson disease in animal models by enhancing axon regeneration, muscle reinnervation and neuromuscular transmission. The effect of DHF on AD neuropathology remains not well defined. In this study we examined whether DHF affects APP processing and cognitive functions in vitro and in vivo. We found that DHF had no significant effect on amyloid β precursor protein (APP), BACE1 and amyloid β protein (Aβ). DHF had little effect on APP processing in cell cultures. DHF treatment did not reduce the deposition of Aβ to form neuritic plaques in the brain of AD model mice APP23/PS45. Furthermore, DHF did not alleviate learning and memory impairments in the AD model mice. Our study suggest that further extensive and careful studies are warranted for considering DHF as a new therapeutic agent for reducing amyloid pathology and alleviating cognitive deficits for AD treatment.
Export Options
About this article
Cite this article as:
Zhou Weitao, Li Xiaoyong, Huang Daochao, Zhou Weihui, Li Tingyu and Song Weihong, No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218124243
DOI https://dx.doi.org/10.2174/1567205012666141218124243 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design
Current Medicinal Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Nanotoxicity: The Toxicity Research Progress of Metal and Metal- Containing Nanoparticles
Mini-Reviews in Medicinal Chemistry bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry BACE Inhibitors as Potential Drugs for the Treatment of Alzheimers Disease: Focus on Bioactivity
Recent Patents on CNS Drug Discovery (Discontinued) The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Mitochondrial Pharmaceutics: A New Therapeutic Strategy to Ameliorate Oxidative Stress in Alzheimer’s Disease
Current Aging Science Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimer’s Disease
Current Alzheimer Research P2X4 Receptors of Microglia in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Roles of Nicotinic Acetylcholine Receptors in Stem Cell Survival/Apoptosis, Proliferation and Differentiation
Current Molecular Medicine Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Synthetic Lethal Interactions in Cancer Therapy
Current Cancer Drug Targets Prion Protein Oligomerization
Current Alzheimer Research Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Regulatory Role of Anesthetics on Heme Oxygenase-1
Current Drug Targets Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology